Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PLEC | Q15149 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31573752 | 1.00 | PKM (0.42) | PKMP2RX7IDO1AGXTKMT2A | |
| SCHEMBL29814990 | 0.83 | PKM (0.40) | PKMP2RX7IDO1AGXTKMT2A | |
| SCHEMBL3712167 | 0.83 | PKM (0.40) | PKMP2RX7IDO1AGXTKMT2A | |
| SCHEMBL458270 | 0.82 | PKM (0.38) | PKMIDO1AGXTKMT2AMEN1 | |
| SCHEMBL30227514 | 0.82 | PKM (0.38) | PKMIDO1AGXTKMT2AMEN1 | |
| Ammonia Solution, Strong SCHEMBL28943169 | 0.80 | PKM (0.37) | PKMIDO1AGXTKMT2AMEN1 | |
| SCHEMBL3637969 | 0.79 | CA2 (0.46) | PKMP2RX7IDO1AGXTKMT2A | |
| SCHEMBL30817945 | 0.79 | CA2 (0.46) | PKMP2RX7IDO1AGXTKMT2A | |
| SCHEMBL596489 | 0.79 | KMT2A (0.37) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL29494112 | 0.79 | PKM (0.39) | PKMP2RX7IDO1AGXTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585588-A1 | BENZIMIDAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Pharmavan Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4143182-B1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12122780-B2 | Pyrimidinyl group-containing tricyclic compound serving as c-Met inhibitor | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2024-10-22 | — | — | US | disclosed |
| CN-118791498-A | Tetracyclic compound, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4404935-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-117720472-A | Benzimidazole compound, and preparation method and application thereof | 苏州沪云新药研发股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024051354-A1 | BENZIMIDAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州沪云新药研发股份有限公司 | 2024-03-14 | — | — | WO | disclosed |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | US | disclosed |
| EP-1317458-A2 | INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2ALPHA ANTAGONISTS | Allergan, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030105064-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | ALLERGAN INC. | 2003-06-05 | — | — | US | disclosed |
| US-6511999-B2 | Treating rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), osteoporosis, peptic ulcers, heart disease, and thrombosis | ALLERGAN, INC. | 2003-01-28 | — | — | US | disclosed |
| US-6509364-B2 | Antiinflammatory agents for reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, broncho-constrictive disorders, excessive bone breakdown, peptic ulcers, heart disease, platelet aggregation and thrombosis | ALLERGAN, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020165399-A1 | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists | ALLERGAN SALES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-20020128233-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | ALLERGAN, INC. | 2002-09-12 | — | — | US | disclosed |
| US-6407250-B1 | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; OSTEOPOROSIS | ALLERGAN SALES, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6369089-B1 | INFLAMMATORY REACTIONS RELATING TO RHEUMATOID ARTHRITIS AND PSORIASIS, REPRODUCTIVE DISORDERS, BRONCHOCONSTRICTIVE DISORDERS (ASTHMA), EXCESSIVE BONE BREAKDOWN (OSTEOPOROSIS), PEPTIC ULCERS, HEART DISEASE, PLATELET AGGREGATION AND | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002022621-A2 | INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS | ALLERGAN INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022620-A2 | INTERHETEROARYL 7-OXABICYCLIC [2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2$G(A) ANTAGONISTS | ALLERGAN, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165399-A1 | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists | PTGIR, PTGER1, TBXA2R | PKM 1995/4885P2RX7 214/4885IDO1 1445/4885 |
| US-20030105064-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | PTGER1, PTGIR, PTGDR | PKM 2632/4885P2RX7 451/4885IDO1 1196/4885 |
| US-12122780-B2 | Pyrimidinyl group-containing tricyclic compound serving as c-Met inhibitor | MET, MYC, METAP1 | PKM 887/4885P2RX7 3072/4885IDO1 3408/4885 |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | PKM 3803/4885P2RX7 123/4885IDO1 516/4885 |
| US-20020128233-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | PTGER1, PTGIR, PTGDR | PKM 2179/4885P2RX7 377/4885IDO1 1238/4885 |
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PKM 2303/4885P2RX7 4487/4885IDO1 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.